Quick Summary

Chanca Piedra (Phyllanthus niruri) is a tropical medicinal plant traditionally used for various health conditions including kidney stones, liver disorders, and immune modulation. Scientific research has evaluated its potential benefits in urolithiasis (kidney stones), liver diseases (including alcoholic hepatitis), antiviral effects, antimicrobial properties, and immunomodulation. Clinical evidence suggests modest efficacy in reducing kidney stone burden and improving antioxidant status in mild alcoholic hepatitis. The herb also shows antimicrobial activity in vitro and potential complementary benefits in stone expulsion therapy. However, robust clinical data remain limited.

What Is It?

Phyllanthus niruri, commonly known as Chanca Piedra, is a tropical herb native to the Amazon rainforest and other tropical regions. It has been traditionally used in South American and Ayurvedic medicine systems for its reputed health benefits, especially in relation to urinary and liver health.

Traditional Uses

  • Support for kidney stone prevention and expulsion
  • Liver health and treatment of liver disorders, including hepatitis
  • Immune system modulation
  • Antiviral and antimicrobial purposes

Active Compounds

The herb contains a range of bioactive metabolites, although detailed chemical characterization varies. Significant compounds include lignans, flavonoids, alkaloids, and other phytochemicals believed to contribute to its biological activities.

Potential Benefits with Evidence Levels

  • Urolithiasis (Kidney Stones) – Low to moderate clinical evidence: Several clinical studies and systematic reviews suggest that Phyllanthus niruri may help reduce stone size and number and facilitate stone expulsion, often as an adjunct to conventional therapies. Meta-analyses showed modest but significant reductions in stone burden. Some randomized controlled trials indicate improved expulsion rates and shorter time to stone passage when combined with standard treatments such as tamsulosin.
  • Liver Health – Limited clinical evidence: One randomized controlled trial in mild to moderate alcoholic hepatitis indicated increased total antioxidant levels and improved appetite after 4 weeks of P. niruri supplementation compared to placebo. However, no significant changes were observed in liver or renal function markers.
  • Antimicrobial Effects – In vitro evidence: Extracts of P. niruri demonstrated inhibitory activity against oral pathogens including Enterococcus faecalis, Porphyromonas gingivalis, and Treponema denticola, showing bacteriostatic effects and membrane disruption in laboratory studies.
  • Immunomodulation – Preclinical evidence: Reviews and preclinical studies report significant immunomodulatory activities of various Phyllanthus species and their metabolites. However, most data derive from crude extracts and lack comprehensive mechanistic or clinical validation.
  • Antiviral Activity – Traditional use and experimental/in silico studies: Phyllanthus species have been explored for antiviral properties, including effects on hepatitis B virus. Clinical data specific to P. niruri against viral infections are limited.

Side Effects

Available clinical studies report good short-term tolerability with minimal adverse effects when Phyllanthus niruri is used alone or in combination with other therapies. Reported side effects during combination therapy included headache, dizziness, nausea, vomiting, postural hypotension, backache, and running nose, with frequencies comparable to control groups. Overall, no serious herb-related adverse effects have been reported, though comprehensive adverse event data remain limited.

Drug Interactions

Data on drug interactions with Phyllanthus niruri are currently insufficient. The potential for interactions with conventional medications is not well defined and warrants further research.

Who Should Avoid It

  • No specific contraindications have been identified in the available literature.
  • Clinical caution is advised for individuals with preexisting liver disease or those using other hepatotoxic agents concurrently.
  • Due to lack of safety data, use during pregnancy and breastfeeding is not recommended without medical supervision.

Evidence Limitations

  • Most clinical studies have small sample sizes and short durations.
  • Considerable heterogeneity exists in study designs, formulations, dosing, and outcome measures.
  • Lack of large, well-designed randomized controlled trials to firmly establish efficacy and safety.
  • Many studies lack comprehensive adverse effect reporting and long-term safety assessments.
  • Mechanistic and pharmacokinetic data are limited.
  • Preclinical immunomodulatory and antiviral findings mostly based on crude extracts without full chemical characterization.
  • Limited data on herb-drug interactions and contraindications.

References

Last Reviewed

June 2024

Disclaimer: This information is for educational purposes only and is not intended as medical advice. Consult a healthcare professional before using any herbal supplement, especially if you are pregnant, breastfeeding, have existing health conditions, or are taking medications.